Higher by 6% in early action are shares of BioLineRX (BLRX).
The company has inked a development and commercialization agreement with JHL Biotech for the monoclonal antibody BL-9020 in Type 1 diabetes.
JHL will process and manufacture the treatment during pre-clinicals, while BLRX will shoulder pre-clinical development.
The companies will share responsibility for clinical development.
JHL will also have commercialization rights in China and SE Asia. (PR)